ASX waiver from requirement to lodge an Appendix 4E

Minneapolis, USA and **Brisbane, Australia 28 February 2025: Anteris Technologies Global Corp.** (NASDAQ: AVR, ASX: AVR) (**Anteris** or the **Company**) advises that the ASX has granted the Company a revised waiver from ASX Listing Rule 4.3A (**Revised Waiver**).

The Revised Waiver is on terms substantially equivalent to those applying under the Company's previous waiver from ASX Listing Rule 4.3A, as disclosed by the Company in its pre-quotation disclosure released on 16 December 2024, being on the terms set out in paragraph 2 of the Annexure to ASX Guidance Note 17, except that the Company is required to provide ASX a copy of its Annual Report on Form 10-K (**Form 10-K**), along with an accompanying cover sheet with the key information set out in section 2 of Appendix 4E, by the earliest of:

(a) the date the Form 10-K is filed with the United States Securities and Exchange Commission (**SEC**); and

(b) the date the Form 10-K is due to be filed with the SEC under U.S. law, being 90 days after the end of reporting period.

The Company expects to file its Form 10-K with the SEC in March 2025.

ENDS

About Anteris®

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR® Transcatheter Heart Valve (**THV**), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information:

860 Blue Gentian Road,
Suite 340
Eagan, MN, 55121
United States
T: +1 651 493 0606
info.us@anteristech.com

Anteris Technologies Global Corp.
BRISBANE | MINNEAPOLIS | GENEVA | MALAGA
anteristech.com

Toowong Tower, Level 3, Suite 302
9 Sherwood Road, Toowong
QLD 4066, Australia
T: +61 1300 550 310
info.au@anteristech.com
ARBN: 677 960 235

Investor Relations
investors@anteristech.com
Anteris Technologies Global Corp.
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
Facebook	www.facebook.com/anteristech
LinkedIn	https://www.linkedin.com/company/anteristech